ResearcherNational Cancer Center HospitalActive in the last 2 years

Noboru Yamamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0787-2851; OpenAlex author ID A5030587345. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. Co-author DOI 10.1038/s41416-025-03286-w ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xinfang Hou · 1 shared paper, 2026 · strength 0.24
- Paper Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. DOI 10.1038/s41416-025-03286-w ↗
Jianzhen Shan · 1 shared paper, 2026 · strength 0.24
- Paper Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. DOI 10.1038/s41416-025-03286-w ↗
Dong Yan · 1 shared paper, 2026 · strength 0.24
- Paper Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. DOI 10.1038/s41416-025-03286-w ↗
Vinod Ganju · 1 shared paper, 2026 · strength 0.24
- Paper Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. DOI 10.1038/s41416-025-03286-w ↗
Rui‐Hua Xu · 1 shared paper, 2026 · strength 0.24
- Paper Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. DOI 10.1038/s41416-025-03286-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.